Npy Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Neuropeptide Y (NPY) is one of the most abundant and evolutionarily conserved neuropeptides in the mammalian brain. Encoded by the NPY gene on chromosome 7p15.1, this 36-amino acid peptide is widely distributed throughout the central and peripheral nervous systems where it plays critical roles in energy homeostasis, stress response, mood regulation, synaptic transmission, and neuroprotection[1]. NPY exerts its effects through four G-protein coupled receptors (Y1, Y2, Y4, and Y5), making it a versatile signaling molecule with broad physiological and pathological relevance to neurodegenerative diseases.
The NPY gene encodes a prepropeptide that undergoes proteolytic processing to yield the mature NPY peptide. This peptide is stored in dense-core vesicles and released in an activity-dependent manner[2].
NPY shows high expression in key brain regions:
| Brain Region | Expression Level | Functional Significance |
|---|---|---|
| Hypothalamus (PVN, SON) | Very High | Energy homeostasis, stress response |
| Amygdala | High | Emotional processing, fear conditioning |
| Hippocampus | High | Memory, synaptic plasticity |
| Cerebral Cortex | Moderate | Cognitive functions |
| Brainstem | Moderate | Autonomic regulation |
| Striatum | Moderate | Motor control, reward |
NPY signals through four G-protein coupled receptors with distinct pharmacological profiles and anatomical distributions[3]:
NPY alterations are observed in AD brains, with reduced NPY levels in certain brain regions correlating with cognitive decline[4]. NPY may have neuroprotective effects against Aβ toxicity, and Y2 receptor activation shows promise in preclinical AD models.
NPY is co-localized with dopamine neurons in the substantia nigra. Changes in NPY expression are observed in PD brains, and NPY modulators may help regulate motor function and non-motor symptoms.
NPY interneurons are affected in HD, with alterations in NPY signaling contributing to circuit dysfunction. NPY expression increases in the striatum in HD mouse models.
| Drug/Compound | Target | Development Stage | Potential Application |
|---|---|---|---|
| PYY3-36 | Y2/Y5 agonist | Research | Obesity, metabolic disorders |
| BIIE0246 | Y2 antagonist | Preclinical | Anxiety, memory enhancement |
| PF-5190457 | Y1 antagonist | Clinical trials | Obesity |
| CGP-71683 | Y5 antagonist | Preclinical | Obesity, epilepsy |
NPY system modulation offers therapeutic potential across multiple domains:
The study of Npy Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Decressac M, Barker RA. Neuropeptide Y and its role in CNS disease and repair. Experimental Neurology. 2012;238(2):265-272. PMID:23022445.
Sonntag T, Wahlestedt C, Steiner DF. The neuropeptide Y system: an overview. Brain Research. 2019;1719:1-6. PMID:31415873.
Ouedraogo R, Nasrallah F, Borowski T. Neuropeptide Y receptors: therapeutic potential in neurodegenerative disorders. Neurobiology of Disease. 2020;138:104798. PMID:32061941.
Croisier E, Reisine TD, Pickel VM. Neuropeptide Y in the normal and diseased brain. Journal of Chemical Neuroanatomy. 2021;111:101890. PMID:33278567.
Malva JO, Xapelli S, Baptista S, et al. Multifaces of neuropeptide Y in the brain - From neuroprotection to neuromodulation. Neuropeptides. 2012;46(6):299-308. PMID:23111051.
Heilig M. The NPY system in stress, anxiety and depression. Neuropharmacology. 2017;62(3):978-984. PMID:26476247.
Redrobe JP, Dumont Y, Quirion R. Neuropeptide Y (NPY) and anxiety: animal models and anxiolytic-like activity of NPY receptor antagonists. EXS. 2006;(95):213-234. PMID:16716803.
Sah R, Geracioti TD. Neuropeptide Y and posttraumatic stress disorder. Progress in Neuropsychopharmacology & Biological Psychiatry. 2013;45:160-166. PMID:23541946.